Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$LTMP Alltemp’s Digital Ad Firm Acquisition Scheduled for September Closing
Press Release | 08/30/2021
WESTLAKE VILLAGE, Calif., Aug. 30, 2021 (GLOBE NEWSWIRE) -- Alltemp, Inc. (“Alltemp” or “the Company”) (OTCPK: LTMP) announces that the Company’s previously announced definitive letter of intent to acquire an established digital advertising and marketing business, Digi Messaging & Advertising, Inc. (“Digi”) through a share exchange agreement, is now scheduled to be effective September 2021.
About Digi Messaging & Advertising, Inc.
Digi Messaging & Advertising, Inc. is a digital marketing and advertising company which currently operates multiple service platforms, including SMS, push notification, short links, email and more. Digi is currently building a consumer facing digital marketing and communications platform-as-a-service to allow enterprises, both large and small, to leverage big data to micro-target customers with disruptive increases in efficiency.
About Alltemp
Alltemp, Inc. has developed a proprietary refrigerant technology called alltemp®, a replacement for many refrigerants that have detrimentally affected the global environment. Alltemp refrigerants have applications in Heating Ventilation and Air Conditioning (HVAC), refrigeration, foam insulation, and industrial solvents. For further information, please go to www.alltempsolutions.com.
Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of The Private Securities Litigation Reform Act of 1995 (the "Act"), as well as Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. In particular, when used in the proceeding discussion, the words "plan," "confident that," "believe," "expect," or "intend to," and similar conditional expressions are intended to identify forward-looking statements within the meaning of the Act and are subject to the safe harbor created by the Act. Such statements about the Company's future expectations, including future revenues and earnings, and all other forward-looking statements are subject to certain risks and uncertainties that are subject to change at any time, and the Company's actual results could differ materially from those expressed in any of the forward-looking statements. Such risks and uncertainties include, but are not limited to, market conditions, the availability of components for and delays in the start of production, general acceptance of the Company's products and technologies, competitive factors, the ability to successfully complete additional financing, and other risks.
Ben Hansel
(720) 288-8495
soon will run
Yes… so we are talking a 130 million OS, with a 60 million float. Reverse merger generating revenue.
Current and a verified profile with OTC markets…
Nice and clean..
and canceling 70M shares?...am i reading that right?
imho
mj
and canceling 70M shares?...am i reading that right?
imho
mj
They are current now and revenue generating
Merger LTMP
Alltemp, Inc. to Acquire Digital Ad Firm
Acquisition brings immediate revenue and exceptional outlook for growth in a market expected to reach $645.8 billion by 2024
https://www.globenewswire.com/news-release/2021/08/11/2279147/0/en/Alltemp-Inc-to-Acquire-Digital-Ad-Firm.html
COLLECTING DOWN HERE...PATIENCE WILL PAY~ $LTMP
They need to get the annual for 2020 and attorney letter show 2020.
--
https://www.otcmarkets.com/stock/LTMP/disclosure
easy to see what is happening here. The person on the Bid , is selling very small amounts 500 , 600 , 100 share lots or about $25 or less.
--
easy to see that on Level 2.. then hoping that someone will sell big in to his BID , so they can get cheap shares.
--
Just hold on to your shares, lock them in at a high, high price sell and with this Float it will not take long. Disclosures out yesterday and Attorney letter today in OTC Markets... Going Pink Current next. Trade accordingly !
$LTMP; Attorney letter now on OTC markets also. Company putting all these disclosures out for a Reason , something in the works. Will be Current right around the corner.
--
https://www.otcmarkets.com/stock/LTMP/disclosure
If you look at this getting Bob Davis the inventor of the process and founder back on the Board says a lot here . it was also a Management change and in sense a Change of Control .
--
They are looking to uplist again on the OTCQB...
--
and at this time it is totally under the RADAR , but today's movement will get folks looking. Lets see what it does , it moves quick on volume that is for sure .
--
all in this disclosure, just took some time to clean it up apparently.
---
https://www.otcmarkets.com/stock/LTMP/news/Alltemp-Inc-Announces-Board-and-Management-Changes?id=272241
Looks like they are getting their reporting in order so the stop sign can be removed and possibly get on the OTCQB. Interesting
look at my post Randy1111, disclosures out on OTC Markets and my post has the link .
I am mobile at the moment. They dropped 4 filings today. Go to their profile on OTC markets
Do you have a link? I am not seeing it on OTC
Filings out with some nice info on them
Wheres the announcement to justify the big jump today. Would be nice to see something at the EOD
This is going to hit the scanners very quickly . filings out during trading day ... Low floater ... great product...
--
WATCH
--
https://www.otcmarkets.com/stock/LTMP/security
$LTMP: HAAAAAAAAAAAAA........ Sure you were. Hit $0.19
REVERSE MERGER BABYYYYYYYYYYYYYYYYYYY
GO $LTMP
Looks like I was right about this POS. Never made it even close to where the pumpers were professing.
What happened to all the refrigerant they were going to sell to the companies that were delivering vaccines. What happened to shares hitting multiple dollar marks. What a laugh Alltemp turned out to be.
meaning? so u r not in ltmp?
possible . im not in that
ltmp should be ready to run as vaccines avail. soon.. just saw rscf tzpc very high up and lt has upgraded facilities etc. and expanded possibly for these times so won't be long before we hear something - very promising
may have to agree as rsc tzp etc are going up looking more closely etc. updates?
i think with ss will tighten up when run comes imho
for an OTC spread is less risky with LTMP, unless rdva really runs to close the gap and will look into that as well. rscf is also looking good all competitors etc. Think the others have storage for longer days than rdva.
that one has 38 mill float... i like these 1 mill loats tiny as share os
rdva spread quite big, rscf reported revenue increasing, looking into whether dilution etc but it seems great..
Seems like a great one, also saw rscf and looking into both, modrna et al will soon need all these as they would want to keep costs low so might use these companies etc.
Just heard about this one 10mill as 5 os 1 mill float real comapny
pinker but they do alot of refridgerating for drug companies
under radar still dirt cheap
symbol is RDVA. Big bids coming in
yeah its makin top ticks and white carries his bags..lol
i might have a real refridge company otcbb under radar .. will hit u soon after my dd
$LTMP: A nice big surge like $TZPC..............
Ready to go down.
That went from $0.05 to $5 last week.
$LTMP getting ready to do the same.
GO $LTMP
$LTMP: Moderna gonna have 40Million vaccines
By end of December according to CEO this morning.
Gotta keep them cool.
$LTMP got what it takes.... maybe a supply contract with FedEx & UPS
GO $LTMP
$LTMP refrigerant sales will go bonkers>>>
Moderna's Vaccine approved............ Requires Refrigeration
Thanks makinezmoney
Moderna Announces Longer Shelf Life for its COVID-19 Vaccine Candidate at Refrigerated Temperatures MRNA
****************************************************
Vaccine candidate now expected to remain stable at standard refrigerator temperatures of 2deg to 8degC (36deg to 46degF) for 30 days, up from previous estimate of 7 days
Shipping and long-term storage conditions at standard freezer temperatures of -20degC (-4degF) for 6 months
mRNA-1273 to be distributed using widely available vaccine delivery and storage infrastructure
No dilution required prior to vaccination
CAMBRIDGE, Mass.--(BUSINESS WIRE)--November 16, 2020--
Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced new data showing that mRNA-1273, its COVID-19 vaccine candidate, remains stable at 2deg to 8degC (36deg to 46degF), the temperature of a standard home or medical refrigerator, for 30 days. Stability testing supports this extension from an earlier estimate of 7 days. mRNA-1273 remains stable at -20deg C (-4degF) for up to six months, at refrigerated conditions for up to 30 days and at room temperature for up to 12 hours.
"We believe that our investments in mRNA delivery technology and manufacturing process development will allow us to store and ship our COVID-19 vaccine candidate at temperatures commonly found in readily available pharmaceutical freezers and refrigerators," said Juan Andres, Chief Technical Operations and Quality Officer at Moderna. "We are pleased to submit these extended stability conditions for mRNA-1273 to regulators for approval. The ability to store our vaccine for up to 6 months at -20deg C including up to 30 days at normal refrigerator conditions after thawing is an important development and would enable simpler distribution and more flexibility to facilitate wider-scale vaccination in the United States and other parts of the world."
Shipping & Long-term Storage: For shipping and longer-term storage, Moderna expects that mRNA-1273 will be maintained at -20degC (-4degF), equal to most home or medical freezer temperatures, for up to 6 months. Using standard freezer temperatures of -20degC (range of -25deg to -15degC or -13deg to 5degF) is an easier and more established method of distribution and storage than deep freezing and most pharmaceutical distribution companies have the capability to store and ship products at -20degC (-4degF) worldwide.
Refrigeration Storage: After thawing, to facilitate storage at points of administration, Moderna expects that mRNA-1273 will remain stable at standard refrigerated conditions of 2deg to 8degC (36deg to 46degF) for up to 30 days within the 6-month shelf life. The stability at refrigerated conditions allows for storage at most pharmacies, hospitals, or physicians' offices.
Room Temperature for Vaccination: Once the vaccine is removed from the refrigerator for administration, it can be kept at room temperature conditions for up to 12 hours.
No Dilution Required at Vaccination Site: The vaccine will not require onsite dilution or special handling, which facilitates vaccination across a range of settings including pharmacies and physicians' offices.
The Company anticipates that it will continue to gather additional stability information over the coming months to assess whether mRNA-1273 can be shipped and stored under increasingly flexible conditions, which will be described in detail following regulatory approval.
The mRNA-1273 COVID-19 vaccine candidate is Moderna's tenth mRNA vaccine to enter the clinic. With its experience in prophylactic vaccine development and investments in mRNA platform and delivery technology, Moderna has developed enhanced manufacturing processes, resulting in proprietary lipid nanoparticle technology that Moderna believes will enable the vaccine to be stored at standard pharmaceutical distribution temperatures.
Moderna is working with the U.S. Centers for Disease Control and Prevention (CDC), Operation Warp Speed and McKesson (NYSE: MCK), a COVID-19 vaccine distributor contracted by the U.S. government, as well as global stakeholders to be prepared for distribution of mRNA-1273, in the event that it receives an Emergency Use Authorization and/or similar global authorizations. The Company is also working closely with the U.S. Food and Drug Administration (FDA) to submit data from its ongoing stability testing for approval.
About mRNA-1273
mRNA-1273 is an mRNA vaccine against COVID-19 encoding for a prefusion stabilized form of the Spike (S) protein, which was co-developed by Moderna and investigators from NIAID's Vaccine Research Center. The first clinical batch, which was funded by the Coalition for Epidemic Preparedness Innovations, was completed on February 7, 2020 and underwent analytical testing; it was shipped to the NIH on February 24, 42 days from sequence selection. The first participant in the NIAID-led Phase 1 study of mRNA-1273 was dosed on March 16, 63 days from sequence selection to Phase 1 study dosing. On May 12, the FDA granted mRNA-1273 Fast Track designation. On May 29, the first participants in each age cohort: adults ages 18-55 years (n=300) and older adults ages 55 years and above (n=300) were dosed in the Phase 2 study of mRNA-1273. On July 8, the Phase 2 study completed enrollment.
Results from the second interim analysis of the NIH-led Phase 1 study of mRNA-1273 in the 56-70 and 71+ age groups were published on September 29 in The New England Journal of Medicine. On July 28, results from a non-human primate preclinical viral challenge study evaluating mRNA-1273 were published in The New England Journal of Medicine. On July 14, an interim analysis of the original cohorts in the NIH-led Phase 1 study of mRNA-1273 was published in The New England Journal of Medicine. mRNA-1273 currently is not approved for use by any regulatory body.
BARDA is supporting the continued research and development of mRNA-1273 with $955 million in federal funding under Contract no. 75A50120C00034. BARDA is reimbursing Moderna for 100 percent of the allowable costs incurred by the Company for conducting the program described in the BARDA contract. The U.S. government has agreed to provide up to $1.525 billion to purchase supply of mRNA-1273 under U.S. Department of Defense Contract No. W911QY-20-C-0100.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including regarding the Company's development of a potential vaccine (mRNA-1273) against the novel coronavirus, the conditions under which mRNA-1273 can be shipped, stored and administered, and the U.S. government's potential purchases of mRNA-1273. In some cases, forward-looking statements can be identified by terminology such as "will," "may," "should," "could", "expects," "intends," "plans," "aims," "anticipates," "believes," "estimates," "predicts," "potential," "continue," or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna's control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others: the fact that there has never been a commercial product utilizing mRNA technology approved for use; the fact that the rapid response technology in use by Moderna is still being developed and implemented; the fact that the safety and efficacy of mRNA-1273 has not yet been established; despite having ongoing interactions with the FDA or other regulatory agencies, the FDA or such other regulatory agencies may not agree with the Company's regulatory approval strategies, components of our filings, such as clinical trial designs, conduct and methodologies, or the sufficiency of data submitted; potential adverse impacts due to the global COVID-19 pandemic such as delays in regulatory review, manufacturing and clinical trials, supply chain interruptions, adverse effects on healthcare systems and disruption of the global economy; and those other risks and uncertainties described under the heading "Risk Factors" in Moderna's most recent Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission (SEC) and in subsequent filings made by Moderna with the SEC, which are available on the SEC's website at www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna's current expectations and speak only as of the date hereof.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201116005606/en/
CONTACT: Moderna Contacts
Media:
Colleen Hussey
Director, Corporate Communications
617-335-1374
Colleen.Hussey@modernatx.com
Investors:
Lavina Talukdar
Senior Vice President & Head of Investor Relations
617-209-5834
Lavina.Talukdar@modernatx.com
SOURCE: Moderna, Inc.
Copyright Business Wire 2020
> Dow Jones Newswires
November 16, 2020 06:52 ET (11:52 GMT)
InvestorsHub NewsWire
this for real or pump?
looks interesting. freeze shipping hot
And, THANKS again, 'WH-JR'!!
Alltemp supplies refrigeration fluids >>> the demand during Operation Vaccine worldwide will be insane
Off website>>>COMMERCIAL REFRIGERATION
This new generation of products offers an optimal solution for all stationary applications, including retail food, transport, industrial and many more.
go $LTMP
Followers
|
30
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
1235
|
Created
|
02/08/10
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |